Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.46 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.44 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.44 |
| ▸ | LOXL2 | Q9Y4K0 | 2/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.41 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | ALPL | P05186 | 1/20 | 0.40 |
| ▸ | CA12 | O43570 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | CA7 | P43166 | 1/20 | 0.40 |
| ▸ | CA9 | Q16790 | 1/20 | 0.40 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.40 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL15065826 | 0.98 | ATM (0.57) | ATMALDH1A1CYP2A6CYP11B1CYP11B2 | |
| SCHEMBL845224 | 0.86 | ATM (0.62) | ATMALDH1A1CYP2A6CYP11B1CYP11B2 | |
| SCHEMBL6978122 | 0.84 | ATM (0.61) | ATMALDH1A1CYP2A6CYP11B1CYP11B2 | |
| SCHEMBL2008389 | 0.84 | ATM (0.66) | ATMALDH1A1CYP2A6CYP11B1CYP11B2 | |
| SCHEMBL14825451 | 0.83 | CYP2C19 (0.64) | ATMALDH1A1CYP2C9CYP2C19CYP4F2 | |
| SCHEMBL7395211 | 0.83 | ATM (0.59) | ATMALDH1A1CYP2A6CYP11B1CYP11B2 | |
| SCHEMBL20094653 | 0.83 | ATM (0.59) | ATMALDH1A1CYP2A6CYP11B1CYP11B2 | |
| SCHEMBL12407009 | 0.83 | ATM (0.59) | ATMALDH1A1CYP2A6CYP11B1CYP11B2 | |
| SCHEMBL3938261 | 0.83 | ATM (0.59) | ATMALDH1A1CYP2A6CYP11B1CYP11B2 | |
| Hydrochloric Acid SCHEMBL7378238 | 0.82 | CYP2C19 (0.62) | ATMALDH1A1CYP2C9CYP2C19CYP4F2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4289813-A2 | INTERMEDIATES TO OBTAIN SUBSTITUTED BENZALDEHYDE COMPOUNDS AND METHODS FOR THEIR USE IN INCREASING TISSUE OXYGENATION | Global Blood Therapeutics, Inc. (US) | 2023-12-13 | — | — | EP | disclosed |
| US-20230255963-A1 | SUBSTITUTED BENZALDEHYDE COMPOUNDS AND METHODS FOR THEIR USE IN INCREASING TISSUE OXYGENATION | GLOBAL BLOOD THERAPEUTICS INC (US) | 2023-08-17 | — | — | US | disclosed |
| US-11691985-B2 | Macrocyclic immunomodulators | CHEMOCENTRYX, INC. (US) | 2023-07-04 | — | — | US | disclosed |
| US-11691985-B2 | Macrocyclic immunomodulators | CHEMOCENTRYX, INC. (US) | 2023-07-04 | — | — | US | disclosed |
| EP-3664793-B1 | MACROCYCLIC IMMUNOMODULATORS | CHEMOCENTRYX INC (US) | 2022-06-29 | — | — | EP | disclosed |
| US-20220125786-A1 | SUBSTITUTED BENZALDEHYDE COMPOUNDS AND METHODS FOR THEIR USE IN INCREASING TISSUE OXYGENATION | GLOBAL BLOOD THERAPEUTICS INC (US) | 2022-04-28 | — | — | US | disclosed |
| US-20220119405-A1 | MACROCYCLIC IMMUNOMODULATORS | CHEMOCENTRYX, INC. | 2022-04-21 | — | — | US | disclosed |
| US-20210290619-A1 | SUBSTITUTED BENZALDEHYDE COMPOUNDS AND METHODS FOR THEIR USE IN INCREASING TISSUE OXYGENATION | GLOBAL BLOOD THERAPEUTICS, INC. | 2021-09-23 | — | — | US | disclosed |
| US-11059834-B2 | Macrocyclic immunomodulators | CHEMOCENTRYX, INC. (US) | 2021-07-13 | — | — | US | disclosed |
| EP-3738434-A1 | INTERMEDIATES TO OBTAIN SUBSTITUTED BENZALDEHYDE COMPOUNDS AND METHODS FOR THEIR USE IN INCREASING TISSUE OXYGENATION | Global Blood Therapeutics, Inc. (US) | 2020-11-18 | — | — | EP | disclosed |
| US-20130190315-A1 | SUBSTITUTED BENZALDEHYDE COMPOUNDS AND METHODS FOR THEIR USE IN INCREASING TISSUE OXYGENATION | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2013-07-25 | — | — | US | disclosed |
| US-20130190316-A1 | SUBSTITUTED HETEROARYL ALDEHYDE COMPOUNDS AND METHODS FOR THEIR USE IN INCREASING TISSUE OXYGENATION | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2013-07-25 | — | — | US | disclosed |
| US-20130190316-A1 | SUBSTITUTED HETEROARYL ALDEHYDE COMPOUNDS AND METHODS FOR THEIR USE IN INCREASING TISSUE OXYGENATION | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2013-07-25 | — | — | US | disclosed |
| WO-2013102145-A1 | SUBSTITUTED HETEROARYL ALDEHYDE COMPOUNDS AND METHODS FOR THEIR USE IN INCREASING TISSUE OXYGENATION | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2013-07-04 | — | — | WO | disclosed |
| WO-2013102142-A1 | SUBSTITUTED BENZALDEHYDE COMPOUNDS AND METHODS FOR THEIR USE IN INCREASING TISSUE OXYGENATION | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2013-07-04 | — | — | WO | disclosed |
| EP-2578569-A1 | HETEROCYCLIC RING COMPOUND AND H1 RECEPTOR ANTAGONIST | ASKA Pharmaceutical Co., Ltd. (JP) | 2013-04-10 | — | — | EP | disclosed |
| US-20130085127-A1 | HETEROCYCLIC COMPOUND AND H1 RECEPTOR ANTAGONIST | ASKA PHARMACEUTICAL CO., LTD (JP) | 2013-04-04 | — | — | US | disclosed |
| US-20130085127-A1 | HETEROCYCLIC COMPOUND AND H1 RECEPTOR ANTAGONIST | ASKA PHARMACEUTICAL CO., LTD (JP) | 2013-04-04 | — | — | US | disclosed |
| US-20050101657-A1 | Pyrrole derivatives for preventing or treating cancer sensitive to hormones; administered with luteininzing hormone releasing hormone derivative | TAKEDA CHEMICAL INDUSTRIES LTD. (JP) | 2005-05-12 | — | — | US | disclosed |
| EP-1466902-A1 | ANDROGEN RECEPTOR ANTAGONISTS | Takeda Chemical Industries, Ltd. (JP) | 2004-10-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11059834-B2 | Macrocyclic immunomodulators | IL2, IL2RA, C3AR1 | ATM 3268/4885ALDH1A1 1925/4885CYP2A6 1133/4885 |
| US-20220119405-A1 | MACROCYCLIC IMMUNOMODULATORS | IL2, IL2RA, C3AR1 | ATM 3268/4885ALDH1A1 1925/4885CYP2A6 1133/4885 |
| US-20130085127-A1 | HETEROCYCLIC COMPOUND AND H1 RECEPTOR ANTAGONIST | HRH2, HRH4, HRH1 | ATM 3898/4885ALDH1A1 2121/4885CYP2A6 1647/4885 |
| US-11691985-B2 | Macrocyclic immunomodulators | IL2, IL2RA, C3AR1 | ATM 3268/4885ALDH1A1 1925/4885CYP2A6 1133/4885 |
| US-20230255963-A1 | SUBSTITUTED BENZALDEHYDE COMPOUNDS AND METHODS FOR THEIR USE IN INCREASING TISSUE OXYGENATION | HBB, HBG2, MB | ATM 1578/4885ALDH1A1 216/4885CYP2A6 522/4885 |
| US-20050101657-A1 | Pyrrole derivatives for preventing or treating cancer sensitive to hormones; administered with luteininzing hormone releasing hormone derivative | SHBG, PRLHR, FSHR | ATM 2400/4885ALDH1A1 2144/4885CYP2A6 915/4885 |
| US-20220125786-A1 | SUBSTITUTED BENZALDEHYDE COMPOUNDS AND METHODS FOR THEIR USE IN INCREASING TISSUE OXYGENATION | HBB, HBG2, MB | ATM 1578/4885ALDH1A1 216/4885CYP2A6 522/4885 |
| US-20130190315-A1 | SUBSTITUTED BENZALDEHYDE COMPOUNDS AND METHODS FOR THEIR USE IN INCREASING TISSUE OXYGENATION | HBB, HBG2, MB | ATM 1578/4885ALDH1A1 216/4885CYP2A6 522/4885 |
| US-20210290619-A1 | SUBSTITUTED BENZALDEHYDE COMPOUNDS AND METHODS FOR THEIR USE IN INCREASING TISSUE OXYGENATION | HBB, HBG2, MB | ATM 1578/4885ALDH1A1 216/4885CYP2A6 522/4885 |
| US-20130190316-A1 | SUBSTITUTED HETEROARYL ALDEHYDE COMPOUNDS AND METHODS FOR THEIR USE IN INCREASING TISSUE OXYGENATION | HBB, HBG2, MB | ATM 2548/4885ALDH1A1 43/4885CYP2A6 232/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.